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Introduction
Quality control of newly synthesized glycoproteins involves 
recognition of misfolded proteins in the ER, where they are 
  either returned to a productive folding pathway or are targeted 
for degradation (Ellgaard and Helenius, 2003). Terminally 
  misfolded glycoproteins are transferred to the cytoplasm for 
proteasomal proteolysis, a process termed dislocation (Wiertz 
et al., 1996a,b).
How the cell distinguishes between newly synthesized 
proteins that have not yet acquired their correct folding state 
and proteins that are terminally misfolded remains a mystery. 
In yeast, genetic analysis has shown the involvement of a lim-
ited set of proteins that contribute to recognition of misfolded 
proteins and their subsequent degradation. The secretory pro-
tein carboxypeptidase Y (CPY), when engineered to yield a 
misfolded product, CPY*, has served as a substrate to identify 
the genetic factors that interfere with its disposal. Der1p was 
identifi  ed as a key player in clearing the yeast ER of mis-
folded CPY* (Knop et al., 1996; Hill and Cooper, 2000; Walter
et al., 2001; Haynes et al., 2002). HMG-CoA reductase, 
which is a transmembrane protein, has similarly served as a 
reporter substrate, allowing Hampton et al. (1996) to defi  ne 
HRD1 and HRD3 as essential for its degradation (Gardner 
et al., 2000, 2001).
Hrd1p/Der3p has ubiquitin ligase activity (E3) and forms 
a complex predominantly with the ubiquitin-conjugating en-
zymes (E2s) Ubc7p and Ubc1p (Bays et al., 2001a), which are 
themselves recruited by the protein Cue1p (Biederer et al., 
1997) to the site of degradation. Hrd3p is required for regulat-
ing the activity and stability of Hrd1p/Der3p (Plemper et al., 
1999), but the function of Hrd3p in protein degradation re-
mains obscure. Hrd3p has a large luminal domain that contains 
different sets of repeated regions that might be involved in 
substrate recognition or form complexes with chaperones. 
Apart from the Ring-H2 ligase Hrd1p/Der3p, there are addi-
tional ER membrane–resident E3s, such as Doa10p (Swanson 
et al., 2001).
Depending on the topology of the ER degradation sub-
strates, different proteins are required for their clearance (Ahner 
and Brodsky, 2004). Substrates with defects in their cytosolic 
domain require Doa10p in yeast. Substrates with defects in their 
luminal portion require the ER lectin Htm1p/Mnl1p, the ubiqui-
tin ligase Hrd1p/Der3p-Hrd3p, Der1p, and proteins involved in 
ER–Golgi traffi  cking (Vashist and Ng, 2004). The two pathways 
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merge when leaving the ER; extraction of the ubiquitin-modifi  ed 
substrate occurs with the assistance of Cdc48p/p97 and its 
  cofactors Ufd1p and Npl4p, culminating in delivery to the pro-
teasome and proteolysis of the substrate (Meyer et al., 2000, 
2002; Ye et al., 2001, 2003; Wang et al., 2004; Park et al., 2005). 
Recent studies analyzed the composition of the protein com-
plexes involved. The Doa10p complex contains Ubc7p, Cue1p, 
Ubx2p, Cdc48p, and its cofactors Ufd1p and Npl4p. These pro-
teins are mainly cytosolic, supporting Doa10p’s role in clearing 
proteins with defects in their cytosolic domain. In addition to 
these proteins, the Hrd1p complex consists of Hrd3p, Der1p, 
the ER lectin Yos9p, and Usa1p (Carvalho et al., 2006; Denic 
et al., 2006). Yos9p has been shown to specifi  cally bind mis-
folded glycoproteins (Bhamidipati et al., 2005; Kim et al., 2005; 
Szathmary et al., 2005). Ubx2p recruits Cdc48p to the membrane 
(Neuber et al., 2005). Usa1p is thought to link Der1p to the 
Hrd1p ligase and thereby assist in clearing luminally misfolded 
proteins from the ER (Ismail and Ng, 2006).
In mammalian cells, the dislocation pathway is more 
complex. Because of the lack of a genetic approach, the dissec-
tion of the degradation pathway in mammalian cells relies on 
the use of substrates, such as mutant versions of the cystic fi  bro-
sis chloride conductance channel (Ward et al., 1995; Bebok 
et al., 1998; Xiong et al., 1999; Kiser et al., 2001), of proteins 
considered terminally misfolded, such as the mutant null Hong 
Kong (NHK) version of the secretory glycoprotein α1 antitryp-
sin (Liu et al., 1999) or the truncated and misfolded version of 
the ER-resident glycoprotein ribophorin (RI), termed RI332 
(Tsao et al., 1992; de Virgilio et al., 1998). Many membrane 
proteins fail to fold properly for lack of the correct partner 
  subunits, such as the unpaired T cell receptor α chain (TCRα; 
Huppa and Ploegh, 1997a,b) or the free immunoglobulin 
μ chain (Fagioli et al., 2001).
Many parallels exist between the yeast and the mamma-
lian glycoprotein quality control systems; however, the players 
in the mammalian system are more numerous. The mammalian 
version of HRD1 is also an ER membrane–resident ubiquitin 
  ligase (Kaneko et al., 2002; Nadav et al., 2003; Kikkert et al., 
2004), which forms a complex with SEL1L, a mammalian 
 orthologue of yeast Hrd3p (Lilley and Ploegh, 2005). Additional 
ubiquitin ligases exist, such as gp78, which has similarity to 
HRD1 in its Ring fi  nger and interacts with UBC7 via its CUE 
domain to ubiquitinate TCRα (Fang et al., 2001). There are at 
least three Der1p homologues in mammals, Derlin-1, -2, and -3, 
which play roles in the disposal of proteins from the ER (Lilley 
and Ploegh, 2004, 2005; Oda et al., 2006).
Among the better-studied routes of membrane glycopro-
tein degradation are the pathways used by human cytomegalo-
virus (HCMV) to destroy the class I major histocompatibility 
complex (MHC) heavy chains (HCs; Ahn et al., 1996). Class 
I MHC products serve as a warning system to alert cytotoxic 
T cells to the presence of virus-derived polypeptides inside the 
cell. The infected cell, thus, invites attack by the cytotoxic T cell 
as a means of eradicating the source of the virus (Tortorella 
et al., 2000). Large DNA viruses, such as HCMV, are under 
strong selective pressure to avoid recognition by the immune 
system. Although widespread amongst the [herpesviridae as a 
strategy to avoid detection, HCMV in particular has amassed a 
set of genes whose products evolved to interfere with assembly 
and intracellular transport of class I MHC products. Amid the 
HCMV-encoded immunoevasins, two, US2 and US11, which 
are small membrane glycoproteins that assist in the degrada-
tion of class I MHC HCs, stand out. US2 and US11 catalyze 
superfi  cially similar reactions, characterized by complex for-
mation of US2 or US11 with their target class I MHC HCs, and 
subsequent extraction of the class I MHC HCs from the ER, a 
process referred to as dislocation (Wiertz et al., 1996a,b). After 
dislocation, the class I HC is destroyed by the proteasome. In 
the presence of proteasome inhibitors, a diagnostic intermedi-
ate in this pathway is the result of attack by N-glycanase on 
the newly dislocated class I MHC HCs (Wiertz et al., 1996a,b; 
Hirsch et al., 2003; Blom et al., 2004). This intermediate con-
sists of a fully cytoplasmic, yet intact, class I MHC HC, de-
void of its N-linked glycan (Misaghi et al., 2004). It occurs 
not only in cells that express US2 or US11, but also in Daudi 
cells, which are unable to assemble class I MHC products for 
lack of the light chain β2-microglobulin (Hughes et al., 1997; 
Radcliffe et al., 2002). Similar deglycosylated intermediates 
have been reported for a misfolded fragment of RI (de Virgilio 
et al., 1998, 1999), but for most other glycoproteins examined, 
degradation occurs without the obvious production of deglyco-
sylated intermediates.
These observations raise the question as to whether the 
pathways exemplifi  ed by US2- and US11-dependent degrada-
tion are indeed emblematic of glycoprotein turnover, as we have 
argued in the past. The furthest advanced is the characterization 
of the US11 pathway, for which we identifi  ed the Derlin-1 pro-
tein as an essential participant (Lilley and Ploegh, 2004; Ye 
et al., 2004). Derlin-1, in turn, forms a complex not only with 
itself and other members of the Derlin family, but also with the 
mammalian Hrd1p and Hrd3p (SEL1L) homologues, as well as 
with Cdc48p/p97 (Lilley and Ploegh, 2005; Ye et al., 2005). The 
US2 pathway is impervious to the action of a dominant-negative 
version of Derlin-1, whereas the US11 pathway is inhibited by 
it (Lilley and Ploegh, 2004). Direct involvement in mammalian 
glycoprotein degradation has now been suggested for compo-
nents of this ER-resident complex, based on interference with 
degradation of α1 antitrypsin NHK by means of overexpression 
and knockdowns of Derlins (Oda et al., 2006). Still, in mamma-
lian cells, much of the relevant data stem from the analysis of 
reactions that depend on the action of the viral accessories US11 
and US2.
We analyze the contributions of a mammalian Hrd3p 
  homologue, SEL1L. We show that reduction of the levels of 
SEL1L by RNA interference results in impairment of US11-
mediated dislocation of class I MHC HC molecules. Expression 
of the same interfering small hairpin RNAs (shRNAs) against 
SEL1L, however, does not affect the US2 pathway. Expression 
of SEL1L shRNAs inhibits the degradation of RI332, which is 
a process that occurs independently of the presence of viral 
  accessories. These results allow us to place SEL1L in a more 
general context of glycoprotein degradation, and suggest that 
SEL1L might be involved in substrate recognition of misfolded 
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Results
SEL1L is part of a mammalian ER multiprotein complex in-
volved in dislocation (Lilley and Ploegh, 2005; Ye et al., 2005). 
SEL1L associates with Derlin-1, -2, p97, and HRD1, as well as 
with additional proteins that remain to be identifi  ed, some or all 
of which may also play a role in dislocation. Some of these pro-
teins are presumably recruited to the site of dislocation through 
SEL1L. SEL1L is predicted to be a type I transmembrane pro-
tein (Fig. S1, available at http://www.jcb.org/cgi/  content/full/
jcb.200605196/DC1) with 5 N-linked glycans (Biunno et al., 
1997). Because the bulk of the SEL1L protein is predicted to 
be in the ER lumen, it is possible that SEL1L fi  rst plays a role 
in substrate recognition and identifi  cation of misfolded pro-
teins, and then recruits them to the site of dislocation. We per-
formed coimmunoprecipitations from steady-state radioactive 
[
35S]methionine/cysteine–labeled cells using mild lysis condi-
tions (2% digitonin) to preserve ER membrane protein com-
plexes, to analyze whether composition of protein complexes 
with SEL1L are conserved for the cell lines used in this study.
Our earlier observations concern the composition of pro-
tein complexes that include the Derlins in the astrocytoma cell 
line U373 (Lilley and Ploegh, 2005). We fi  rst  verifi  ed  that 
the types of complexes detected in U373 cells are not cell type–
specifi  c, but occur in other cell lines as well (Fig. 1). We were 
particularly interested in cell lines that would lend themselves 
to transient transfection experiments (Fig. 1, HeLa cells, lanes 
1–4) and in multiple myeloma cells (Fig. 1, MM1.S cells, lanes 
5–8), which represent cells with a high secretory capacity, and, 
presumably, a correspondingly pronounced requirement to clear 
misfolded proteins from the ER.
When we performed immunoprecipitations with antibod-
ies against Derlin-1, -2, and SEL1L, the composition of the 
complexes obtained was very similar to that reported for U373 
cells (Lilley and Ploegh, 2005). We conclude that the multipro-
tein complexes, which were initially identifi  ed for U373 cells, 
are representative of the complexes detected in other, unrelated 
cell types. The pattern of the protein complexes is equivalent in 
all tested cell lines, including U373 (astrocytoma), HeLa (epi-
thelial), 293T, MM1.S (multiple myeloma), and C6 (Rat  glioma) 
cells. SEL1L is likely to be a crucial component of a ubiquitous 
ER-dislocation complex.
When we analyzed the half-life of SEL1L, we found that 
it decays with a half-life of  180 min (Fig. 2, lanes 1, 3, and 5). 
SEL1L degradation appears to be proteasome-dependent be-
cause it is inhibited by inclusion of the proteasome inhibitor 
ZL3VS (Fig. 2, lanes 7, 9, and 11). SEL1L remains completely 
susceptible to endoglycosidase H (EndoH) treatment, suggest-
ing that SEL1L is an ER protein and does not traffi  c through the 
secretory pathway (Fig. 2, lanes 2, 4, 6, 8, 10, and 12).
To address whether SEL1L plays a direct role in the pro-
cess of dislocation from the ER, we generated small hairpin 
RNAs (shRNAs) that target SEL1L or a control unrelated 
  protein (GFP) using the pRETRO-SUPER in vivo expression 
system (Brummelkamp et al., 2002). The shRNA plasmids re-
duced SEL1L protein levels to 30% compared with control 
cells (Fig. 3 a). 
We analyzed the stability of class I MHC HCs in cells 
  expressing US11 and the SEL1L shRNAs. The fate of HC is 
best analyzed in a pulse-chase experiment in view of the rate of 
dislocation (t1/2 = 2–5 min) in US11 cells (Wiertz et al., 1996a). 
In cells expressing US11 and shRNAs against GFP (control 
cells), HC disappears completely when proteasome inhibitors 
are not included (Fig. 3 b, 1, lanes 2 and 3). In cells expressing 
SEL1L shRNA, the rate of degradation of class I MHC HC is 
much reduced (Fig. 3 b, 1, lanes 8 and 9).
In the presence of the proteasome inhibitor ZL3VS, the 
deglycosylated class I MHC HC accumulates as the diagnostic 
intermediate that characterizes the dislocation reaction. In con-
trol shRNA US11 cells, complete conversion to the deglycosyl-
ated form of HC is seen after 30 min of chase (lane 6). In SEL1L 
knockdown cells, >50% of HC remains in its fully glycosylated 
form. This persistence of HC is attributable to compromised 
dislocation, as only  50% of HC accesses the cytosolically dis-
posed N-glycanase (Fig. 3, b, 1 [lanes 11 and 12], and c).
This impairment in dislocation is not caused by reduced 
levels of US11 in SEL1L knockdown cells, as US11 is expressed 
at comparable levels, nor is it caused by aberrant ER insertion 
and processing of US11, as determined by normal cleavage of 
Figure 1.  SEL1L is part of a conserved complex in many cell types. 
Immuno  precipitation from digitonin lysates of HeLa (lanes 1–4) or MM1.S 
(lanes 5–8) cells pulse-labeled for 16 h (steady state) were performed with 
control rabbit IgG, anti–Derlin-1, anti–Derlin-2, and anti-SEL1L antibodies, 
respectively. The positions of the relevant proteins are indicated.JCB • VOLUME 175 • NUMBER 2 • 2006  264
US11’s signal sequence (Rehm et al., 2001) in SEL1L knock-
down cells (Fig. 3 b, 2).
Because SEL1L is a mammalian homologue of yeast 
Hrd3p, we looked for possible parallels between the two sys-
tems that could account for the observed phenotype. Hrd1p, 
which is a yeast E3 ligase known to be necessary for degrada-
tion of some substrates (Bays et al., 2001b; Bordallo and Wolf, 
1999; Hampton et al., 1996; Kikkert et al., 2004; Nadav et al., 
2003), is regulated by Hrd3p and destabilized in ∆hrd3 yeast 
(Gardner et al., 2000; Plemper et al., 1999). Therefore, we ana-
lyzed HRD1 levels in SEL1L knockdown cells to examine 
whether inhibition of dislocation is primarily caused by reduced 
levels of SEL1L or, alternatively, attributable to a reduction in 
HRD1 levels. We fi  nd that HRD1 is stable throughout the chase 
periods over which HC dislocation occurs (Fig. 3 b, 3).
A comparable reduction of SEL1L levels in US2 cells 
(Fig. 4 a) has no observable effect on HC dislocation. In US2 
cells exposed to proteasome inhibitor, we see conversion of 
  almost all class I MHC HCs to the deglycosylated species after 
30 min (Fig. 4 b, 1, lane 6). In US2 cells, knockdown of SEL1L 
results in a rate of dislocation equal to that in control cells and 
yields a pattern noticeably distinct from that seen for the SEL1L 
knockdown in US11 cells (Fig. 4, b [1] and c). US2 levels are 
also comparable for control and SEL1L knockdown cells (Fig. 
4 b, 2). Unimpaired degradation in US2 cells of class I MHC 
HCs is consistent with the idea that US11 co-opts a conserved 
complex to catalyze degradation of class I MHC HC, whereas 
US2 utilizes a distinct pathway (Lilley and Ploegh, 2004, 2005; 
Loureiro et al., 2006). This result is all the more striking be-
cause US2 and US11 target the same set of substrates, class I 
MHC products.
Given the homology of SEL1L to Hrd3p, it is likely that 
SEL1L plays a general role in glycoprotein turnover, similar to 
what was shown for the Der1p homologues of the Derlin pro-
teins (Lilley and Ploegh, 2004; Oda et al., 2006). Thus far, the 
only substrates that for their dislocation depend on Derlin-1 are 
class I MHC HCs in US11-expressing cells and US2 itself 
(Lilley and Ploegh, 2004). Overexpression and knockdowns of 
Derlin-2 and -3 have been reported to affect the half-life of α1 
antitrypsin NHK (Oda et al., 2006).
Therefore, we examined other model substrates of ER dis-
location for their susceptibility to inhibition by a knockdown of 
SEL1L. We analyzed the effect of SEL1L shRNAs on the deg-
radation of a mutant version of RI, RI332. The RI332 mutant lacks 
Figure 2.  SEL1L is an unstable ER membrane glycoprotein. 
Immunoprecipitation from NP-40 lysates of U373 cells 
pulse-labeled for 20 min and chased for the indicated 
time points in the absence (lanes 1–6) or presence 
(lanes 7–12) of ZL3VS were performed with anti-SEL1L 
  antibodies. Half of the eluates were treated with EndoH 
(lanes 2, 4, 6, 8, 10, and 12).
Figure 3.  shRNAs targeting SEL1L impair 
US11-mediated dislocation of class I MHC HC. 
(a) US11 cells were transduced with virus en-
coding shRNAs against GFP (control cells) or 
against SEL1L (knockdown cells) and analyzed 
for levels of SEL1L by immunoblotting with 
anti-SEL1L antibodies and anti–protein disul-
ﬁ  de isomerase (PDI) antibodies as a loading 
control. (b) Control and knockdown cells were 
pulse-labeled for 10 min and chased for the in-
dicated time points. Immunoprecipitation from 
SDS lysates for class I MHC HC (1), US11 (2), 
and HRD1 (3) were performed using respec-
tive antibodies. (c) Quantitation of the amount 
of glycosylated to deglycosylated HC from 
shRNA GFP (control) and shRNA SEL1L (knock-
down) cells treated with ZL3VS.ROLE OF SEL1L IN ER DISLOCATION • MUELLER ET AL. 265
the C terminus of RI; unlike the very stable RI protein, the RI332 
fragment has a half-life of  90 min (Tsao et al., 1992; 
de Virgilio et al., 1998, 1999). We chose RI332 as substrate because 
its mode of disposal includes an intermediate that is the product 
of N-glycanase activity (Kitzmuller et al., 2003). We transiently 
transfected RI332 into HeLa cells, which had been stably trans-
duced with shRNAs against either GFP or SEL1L (Fig. 5 a). 
SEL1L knockdown cells showed a reduction of SEL1L levels to 
40% of controls. We transfected a GFP expression plasmid into 
both GFP shRNA and SEL1L shRNA HeLa cells as a transfec-
tion control, as well as a control for shRNA-mediated knock-
down in the HeLa shRNA GFP control cells. The percentage of 
cells expressing GFP was equivalent ( 40%), but, as expected, 
the intensity of the GFP signal was much lower in GFP shRNA 
cells (unpublished data).
Two days after transfection, cells were harvested, pulsed 
for 20 min with [
35S]methionine, and chased for 0, 90, and 180 
min. Immunoprecipitation with anti-RI antibody retrieves both 
the truncated and wild-type RI. In control shRNA GFP HeLa 
cells,   90% of truncated RI332 is degraded after 180 min, 
whereas in SEL1L knockdown cells, we see a considerable sta-
bilization of RI332;  40% of RI332 remains (Fig. 5, b [lanes 3 
and 6] and c). The observed stabilization of RI332 is all the more 
noteworthy as the achieved stable knockdown of SEL1L in 
HeLa cells is ≥40% (Fig. 5 a). Wild-type RI (a stable protein in 
the ER) remains unaffected, and expression of SEL1L shRNA 
does not affect overall glycosylation as assessed by class I MHC 
HC and US11 maturation and glycosylation earlier.
Does SEL1L speciﬁ  cally interact 
with misfolded proteins in the ER?
Because SEL1L has a long luminal domain with tetratricopep-
tide repeats (TPRs; Sel1 repeats of the TPR family; Fig. S1), a 
domain structure suggested to mediate protein–peptide interac-
tions, we determined whether SEL1L interacts with misfolded 
proteins, and whether SEL1L can discriminate between prop-
erly folded and misfolded proteins. We examined association of 
RI332 with SEL1L by immunoprecipitating for SEL1L from ex-
tracts of cells transiently transfected with RI332 and lysed under 
mild conditions. We found that RI332 interacts with SEL1L (Fig. 
6 b, lane 1), and we confi  rmed this interaction in re-immuno-
precipitation experiments (Fig. 6 b, lane 2). We were unable to 
detect the full length, and presumably properly folded, form of 
RI in the re-immunoprecipitation, although the presence of trace 
amounts of full-length RI remains a possibility, as misfolded 
RI332 is in excess over endogenous RI (Fig. 6 a). As a second 
specifi  city control, we confi  rmed that the deglycosylated dislo-
cation intermediate of RI332, which accumulates in the cytosol 
when cells are treated with proteasome inhibitor, does not inter-
act with SEL1L (Fig. 6 and Fig. S2, available at http://www.jcb.
org/cgi/content/full/jcb.200605196/DC1).
We transiently transfected the same HeLa cell lines that 
had been stably transduced with shRNAs targeting either SEL1L 
or GFP with TCRα. TCRα is likely degraded because of the un-
paired charged residues in its transmembrane domain when its 
proper partner subunits (TCRβ and CD3 complex) are not coex-
pressed (Cosson et al., 1991). Cells were labeled for 20 min 
with [
35S]methionine and chased for 0, 2, and 4 h (Fig. 7 a), and 
the amount of TCRα remaining at each time point was quanti-
tated (Fig. 7 b). We see a moderate effect of a SEL1L knock-
down on TCRα degradation; after 4 h of chase, 25% of TCRα 
remains in the shRNA GFP control cells, whereas in SEL1L 
knockdown cells, 35% remains (Fig. 7 b). The effect is likely to 
be less pronounced for TCRα than for RI332 because TCRα 
would be classifi  ed as misfolded because of recognition of un-
paired charges in its transmembrane domain, whereas RI332 is 
an entirely luminal protein. From yeast, we know that the site 
of misfolding is crucial for the recruitment of specifi  c substrate 
recognition proteins (Ahner and Brodsky, 2004; Carvalho et al., 
2006). Another explanation for the poor interference with TCRα 
degradation could be the level of SEL1L knockdown to no more 
than 40%. Interference with the degradation of TCRα might 
Figure 4.  shRNAs targeting SEL1L do not impair US2-
mediated dislocation of class I MHC HC. (a) US2 cells 
were transduced with virus encoding shRNAs against GFP 
(control cells) or against SEL1L (knockdown cells) and ana-
lyzed for levels of SEL1L by immunoblotting with anti-SEL1L 
antibodies and anti-PDI antibodies as a loading control. 
(b) Control and knockdown cells were pulse-labeled for 
10 min and chased for the indicated time points. Immuno-
precipitation from SDS lysates for class I MHC HC (1) and 
US2 (2) were performed using respective antibodies. 
(c) Quantitation of the amount of glycosylated to deglyco-
sylated HC from shRNA GFP (control) and shRNA SEL1L 
(knockdown) cells treated with ZL3VS.JCB • VOLUME 175 • NUMBER 2 • 2006  266
  require a greater reduction in SEL1L levels than attained with 
the present knockdown strategies.
Discussion
SEL1L is essential for dislocation of class I MHC molecules 
from the ER in cells that express US11. Upon reduction of 
the levels of the SEL1L protein, fully glycosylated, EndoH-
  sensitive class I MHC HCs accumulate in the ER. In contrast, 
the US2 pathway is not perturbed by reduction of SEL1L  protein 
levels. These results underscore the relevance of other observa-
tions that place US11 and US2 in distinct pathways, e.g., based 
on their susceptibility to interference with Derlin-1 function; a 
Derlin-1
GFP fusion protein impairs degradation of class I MHC 
molecules via the US11-dependent, but not via the US2-dependent, 
pathway (Lilley and Ploegh, 2004).
There are several lines of evidence to suggest that US2 
and US11 use different principles to accelerate degradation of 
class I MHC molecules, in addition to the aforementioned dif-
ference in Derlin-1 dependency. US2 must exploit features in its 
relatively short cytoplasmic tail, whereas tailless US11 remains 
dislocation-competent (Furman et al., 2002; Loureiro et al., 
2006). The preference of the US2 and US11 pathways for folded 
and unfolded class I MHC molecules appears to be different 
(Blom et al., 2004), as is the requirement for elements in the tail 
of the class I MHC molecules themselves (Wiertz et al., 1996b). 
Our data now establish that the US11, but not the US2, pathway 
is sensitive to a SEL1L knockdown. These distinctions are all 
the more remarkable given the similarities of the substrates tar-
geted for degradation, the identical class I MHC HCs in the 
same parent cell line.
We also report that down-regulation of SEL1L affects the 
degradation of a RI fragment whose route of degradation is 
similar to what we have described for class I MHC products tar-
geted by the HCMV immunoevasins (Hughes et al., 1997; 
Kitzmuller et al., 2003). In the presence of proteasome inhibi-
tors, a deglycosylated RI332 species, the product of N-glycanase 
digestion, is observed (Kitzmuller et al., 2003). Our data, thus, 
support the notion that human SEL1L is the orthologue of yeast 
Hrd3p because reduction of SEL1L levels perturbs the degrada-
tion of a misfolded substrate, RI332.
We conclude that SEL1L and its associated partners oper-
ate in a pathway that is neither restricted to class I MHC prod-
ucts, nor strictly dependent on the involvement of virus-encoded 
Figure 5.  Dislocation of truncated RI (RI332) is impaired by shRNAs target-
ing SEL1L. (a) HeLa cells were stably transduced with either shRNAS 
against GFP (control cells) or SEL1L (knockdown cells) and analyzed for 
levels of SEL1L by immunoblotting with anti-SEL1L antibodies and anti-PDI 
antibodies as a loading control. (b) Control and knockdown cells were 
transiently transfected with RI332. 36 h after transfection, these cells were 
pulse-labeled for 20 min and chased for the indicated time points. Immuno-
precipitation from SDS lysates were performed using anti-RI I antibodies. 
(c) The bar diagram shows quantitation of the experiment. Error bars rep-
resent the SD of three independent experiments.
Figure 6.  SEL1L interacts with RI332 293T cells transfected with RI332 that 
were pulse-labeled to steady-state for 5 h in the presence of 10 𝗍M of the 
proteasome inhibitor ZL3VS. Immunoprecipitations from digitonin lysates 
were performed with anti-SEL1L antibodies. The anti-SEL1L immunoprecipi-
tate was either analyzed directly (b, lane 1) or reimmunoprecipitated 
  sequentially using anti-RI I antibodies (b, lane 2) or anti-SEL1L antibodies 
(b, lane 3). (a) Input levels of endogenous RI and overexpressed RI332. 
  Immunoprecipitates were resolved on a 12% SDS polyacrylamide gel. 
  Asterisk represents a presumably processed version of RI332 in the ER.ROLE OF SEL1L IN ER DISLOCATION • MUELLER ET AL. 267
proteins. The concept of physically extracting proteins from the 
ER and their delivery to the cytosolic proteasome achieves the 
compartmentalization required to spare nascent and properly 
folded ER proteins from premature degradation. The advan-
tages of studying the pathways for the HCMV US2 and US11 
proteins are the speed with which degradation occurs and the 
involvement of well-characterized substrates, the class I MHC 
products. The available antibodies allow an easy distinction be-
tween various folding intermediates, and the occurrence of the 
tell-tale deglycosylated degradation intermediate is an accurate 
reporter for its localization and for the dislocation reaction 
per se (Wiertz et al., 1996a,b). We have taken advantage of the 
fact that US2 and US11 attract very similar substrates in one 
and the same cell, yet apparently do so by mechanistically dif-
ferent pathways (Furman et al., 2002; Lilley and Ploegh, 2004; 
Loureiro et al., 2006).
This does raise the question, however, of whether the 
  results obtained for these HCMV immunoevasins and class I 
MHC substrates can be extrapolated to other substrates, and to 
pathways that operate independently of viral accessories.
To our knowledge, the observation that SEL1L is involved 
in the degradation of RI332, a known dislocation substrate, is the 
fi  rst example for mammalian cells that directly places SEL1L in 
a pathway of protein degradation. The dominant-negative ver-
sion of Derlin-1, Derlin-1
GFP, had no effect on RI332 degradation 
(unpublished data), making the mammalian degradation path-
ways even more complex. The different degradation pathways 
that, in yeast, process distinct types of substrates (luminally vs. 
cytoplasmically exposed proteins) likely operate in mammals, 
too, but involve more factors that comprise the different com-
plexes. In addition to the multiple Derlin proteins, ubiquitin 
  ligases, and lectins involved in mammalian ER degradation, 
there is an additional SEL1L-like protein in mammals that bears 
homology to Hrd3p (Fig. S1). Whether this protein binds to 
HRD1 and participates in the degradation of misfolded proteins 
remains to be determined.
In yeast, substrates that require Der1p for degradation re-
quire Hrd1p/Hrd3p and usually belong to the set of completely 
luminal substrates. In mammals, depending on the substrate, 
Derlin-1 and SEL1L can act in concert with each other, as we 
show for class I MHC HC, but SEL1L can also assist in the 
degradation of substrates independently of Derlin-1, as is the 
case for RI332. A recent study suggests that, in yeast, Hrd3p and 
Der1p can recruit substrates independently of each other (Gauss 
et al., 2006b).
We also examined a substrate that is recognized as mis-
folded by means of charged residues in its transmembrane 
 domain, TCRα. We observed modest stabilization when SEL1L 
expression is compromised. The lesser effect on this substrate 
compared with RI332, which is an entirely luminal substrate, 
  further suggests that the nature of the substrate determines 
  recruitment of an otherwise conserved complex. We cannot 
  exclude that different degradation substrates require different 
levels of SEL1L. Perhaps TCRα degradation usually proceeds 
in the presence of very few SEL1L molecules.
The ER machinery involved in recognition of substrates 
is likely to be specifi  c for certain substrates, but the details of 
recognition of misfolded substrates in yeast are no better 
  resolved than in mammalian cells. In yeast, Yos9p, a putative 
lectin protein, is involved in the degradation of a membrane-
bound version of CPY* (Buschhorn et al., 2004) and might be 
involved in identifying and targeting substrates for degradation 
(Bhamidipati et al., 2005; Kim et al., 2005; Szathmary et al., 
2005). A recent study suggests that proteins that are misfolded 
in yeast bind to Hrd3p, which itself binds to Yos9p. Yos9p then 
ensures that only terminally misfolded proteins are being de-
graded (Gauss et al., 2006a). Another avenue to identifi  cation 
of misfolded glycoproteins might be through their high-mannose–
containing, N-linked glycan modifi  cations (Helenius and Aebi, 
2004). Mannose residues are trimmed in the ER by the enzyme 
α-mannosidase I (Hosokawa et al., 2003; Wu et al., 2003), 
  generating a Man8GlcNac2 tag implicated in targeting glyco-
proteins for degradation (Ellgaard and Helenius, 2003). 
Proteins with this tag bind to calnexin and other lectins, the 
ER degradation-enhancing mannosidase-like (EDEM) proteins, 
EDEM1 and EDEM2 (Hosokawa et al., 2001, 2003; Mast et al., 
2005; Olivari et al., 2005), which then target some glycopro-
teins for degradation (Molinari et al., 2003; Ahner and Brodsky, 
2004; Oda et al., 2006) There is a mammalian orthologue of 
Yos9p, OS-9, whose function is unknown but might be critical 
in degradation of certain substrates.
Similar to EDEM, SEL1L might be involved in substrate 
recognition and bind to a subset of misfolded proteins. SEL1L 
is remarkably conserved, and contains several repetitive struc-
tural and functional domains (sel1-like repeats of the TPR family) 
and a type II fi  bronectin domain in its large luminal part that 
Figure 7.  TCR𝗂 degradation is moderately slowed by shRNAs targeting 
SEL1L. The same control and knockdown cells used in Fig. 5 were   transiently 
transfected with TCRα. 36 h after transfection these cells were pulse-  labeled 
for 20 min and chased for the indicated time points. Immunoprecipitation 
from SDS lysates were performed using anti–TCRα-antibodies. (c) The his-
togram shows mean quantitation of two independent experiments. JCB • VOLUME 175 • NUMBER 2 • 2006  268
could bind to chaperones or misfolded proteins. Alternatively, 
SEL1L might recruit substrate recognition proteins such as 
EDEM or OS-9 through its type II fi  bronectin domain at its N 
terminus. In yeast, Hrd3p’s N-terminal domain is essential for 
its function in ER degradation, and its central region required 
for interaction with Hrd1p (Gardner et al., 2001).
SEL1L forms a 1:1 stoichiometric complex with HRD1 
in mammalian cells (Lilley and Ploegh, 2005), but until now, 
SEL1L’s direct involvement in protein degradation has not been 
shown. Thus, we conclude that SEL1L, based on its associated 
partners, its direct involvement in glycoprotein degradation, and 
its structural relationship to yeast Hrd3p, helps select proteins 
for entry into a degradative pathway. Our data provide the fi  rst 
functional evidence to support the notion that SEL1L is indeed 
the orthologue of yeast Hrd3p.
Materials and methods
Antibodies, DNA constructs, and cell lines
Anti-HC, anti-US2, anti-US11, anti–Derlin-1, anti–Derlin-2, and anti-SEL1L 
antibodies have been described previously (Tortorella et al., 1998; Gewurz 
et al., 2002; Lilley et al., 2003; Lilley and Ploegh, 2004, 2005).
Anti-RI332 antibodies and the RI332 DNA construct were a gift from 
N.E. Ivessa (University of Vienna, Vienna, Austria) and G. Kreibich (New 
York University Medical Center, New York, NY), anti-TCRα antibodies were 
purchased from Sigma-Aldrich, and anti-HRD1 antibodies were a gift from 
E. Wiertz (Leiden University, Leiden, Netherlands; Kikkert et al., 2004).
The TCRα expression construct was described previously (Huppa 
and Ploegh, 1997a).
For stable shRNA expression, the pRETRO-SUPER vector was used 
(Brummelkamp et al., 2002).
U373-MG astrocytoma/glioblastoma cells, US2, US11, 293T, and 
HeLa cells were cultured as previously described (Rehm et al., 2001; Lilley 
et al., 2003).
MM1.S cells were cultured in RPMI containing 10% FCS.
Metabolic labeling, immunoprecipitation, endoglycosidase H digestion, 
gel electrophoresis, immunoblotting, and transient transfections
These procedures were similar to those described in Lilley and Ploegh 
(2005). Treatment of cells with the proteasome inhibitor ZL3VS has been 
previously described (Shamu et al., 1999). Analysis of class I MHC HC 
stability in US11 and US2 cells, pulse-labeling, cell lysis (SDS and digito-
nin), and re-immunoprecipitations have been previously described (Lilley 
et al., 2003). NEM (N-ethylmaleimide) was included in digitonin and SDS 
lysis at a concentration of 2.5 mM. SDS PAGE has been previously 
  described (Ploegh, 1995).
293T cells were transiently transfected with Trans-IT (Takara Mirus 
Bio) according to the manufacturer, using 2–5 μg of DNA for transient 
transfections and 10 μg of total DNA for virus production in 10-cm dishes. 
HeLa cells were transiently transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer, using 2–5 μg for transient transfections 
in 10-cm dishes.
Immunoprecipitates were treated with EndoH according to the 
  manufacturer (New England Biolabs).
The program ImageJ (National Institutes of Health) was used for 
quantitating bands on ﬁ  lm.
SEL1L knockdown
19-nt target sequences in SEL1L were chosen according to the online 
  design software available from the Whitehead Institute webpage (http://
jura.wi.mit.edu/siRNAext/). Sense and antisense strands were annealed 
to form the shRNA template insert and ligated into the retroviral vector 
pRETRO SUPER (Brummelkamp et al., 2002) to generate shRNA construct 
s2 for stable shRNA expression and for transient transfection (19mer 
  sequences; G  G  C  T  A  T  A  C  T  G  T  G  G  C  T  A  G  A  A   and T  T  C  T  A  G  C  C  A  C  A  G  T  A  T  A  G-
C  C  , respectively). As a control, the unrelated construct (GFP shRNA) targeting 
the enhanced GFP reporter was used (Lilley and Ploegh, 2005). All con-
structs were sequence-conﬁ   rmed and used for virus production in HEK 
293T cells (Soneoka et al., 1995). pRETRO-transduced U373 cells and 
HeLa cells were selected with 0.375 μg/ml and 1 μg/ml puromycin, 
  respectively, as previously described (Lilley and Ploegh, 2005).
Online supplemental material
Fig. S1 shows a schematic of the Hrd3p homologues in mammals. Fig. 
S2 shows SEL1L interacting with RI332 293T cells transfected with RI332. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200605196/DC1.
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